I4C 2.0: immunotherapy for cure
Active Cooperative Agreement Awarded Last action
- Award ID
- UM1AI164556
- Recipient
-
Beth Israel Deaconess Medical Center, Inc. UEI C1CPANL3EWK4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $28,008,139
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 75% complete
- Originally
- Funding
-
- $27,799,806.00 Federal
- $208,333.00 Non-federal
- Funding agency
- National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health, Department of Health and Human Services
- Place of performance
- Boston, MA 02215, USA
Award details come from USAspending.gov.
Description
- Abstract
- The goals of I4C 2.0 are to advance our scientific understanding of the viral reservoir and to develop immunologic strategies for HIV-1 remission and eradication by a highly collaborative and multifaceted research program involving partnerships among academia, industry, government, and the community. Our overall hypothesis is that multiple immunologic strategies will need to be explored and combined to achieve long-term, art- free virologic control or complete virus eradication, with the goal of selecting combination regimens to advance into clinical development by the end of the proposed period of support. We propose three research foci, a management and operations section, and a community engagement section. Focus 1 (mechanistic basis of reservoir targeting and viral persistence) aim 1. To define a virologic, immunologic, and transcriptomic signature of viral persistence and rebound and to determine how immunologic strategies target the viral reservoir in nhps and humans aim 2. To define drivers of clonal expansion and persistence of the replication-competent viral reservoir in nhps and humans to enhance reservoir control and elimination focus 2 (novel strategies for sustained virus remission) aim 1. To evaluate innovative immune engineering strategies that provide long-term t cell or ENV-directed immune control, including therapeutic vaccines, car-t cells, and engineered b cells aim 2. To combine approaches that augment humoral and cellular immune responses to achieve sustained immunosurveillance and long-term art-free virologic control focus 3 (novel strategies for virus eradication) aim 1. To evaluate innovative strategies for rapid elimination of the majority of the viral reservoir, including improved lras combined with bnabs, activated NK cells, and car-t cells aim 2. To combine the most effective approach to rapidly eliminate the majority of the viral reservoir with sustained immunosurveillance to eliminate the residual viral reservoir management and operations (MO) section community engagement (CE) section
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $166,667 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $208,333 | $0 | |
| Amendment | $125,000 | $0 | |
| Amendment | $3,986,976 | $0 | |
| Amendment | $3,986,976 | $0 | |
| Amendment | $166,667 | $0 | |
| Amendment | $125,000 | $0 | |
| Amendment | $3,756,388 | $0 | |
| Amendment | $208,333 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $208,333 | $0 | |
| Amendment | $208,333 | $0 | |
| Amendment | $166,667 | $0 | |
| Amendment | $125,000 | $0 | |
| Amendment | $166,667 | $0 | |
| Amendment | $208,333 | $0 | |
| Amendment | $4,011,094 | $0 | |
| Amendment | $166,667 | $0 | |
| Amendment | $208,333 | $0 | |
| Amendment | $208,333 | $0 | |
| Amendment | $125,000 | $0 | |
| Amendment | $4,238,063 | $0 | |
| Amendment | $166,667 | $0 | |
| Amendment | $166,667 | $0 | |
| Amendment | $166,667 | $0 | |
| Amendment | $208,333 | $0 | |
| Amendment | $125,000 | $0 | |
| Amendment | $166,667 | $0 | |
| Original award | $208,333 | $208,333 |
Show all 43
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The General Hospital Corporation | $1,216,389 | |
| The General Hospital Corporation | $1,375,290 | |
| Case Western Reserve University | $388,014 | |
| The Trustees Of The University Of Pennsylvania | $470,523 | |
| University Of Pittsburgh - Of The Commonwealth System Of Higher Education | $383,751 | |
| University Of Pittsburgh - Of The Commonwealth System Of Higher Education | $1,509,968 | |
| Aids Vaccine Advocacy Coalition Inc. | $399,950 | |
| The Johns Hopkins University | $1,476,816 | |
| Yale Univ | $84,182 | |
| University Of Massachusetts Lowell | $427,137 | |
| University Of Southern California | $396,827 | |
| The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | $1,490,240 |
Show all 12
Quick answers
Who received award UM1AI164556?
UM1AI164556 was awarded to Beth Israel Deaconess Medical Center, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 16, 2021.
How much is award UM1AI164556 worth?
$28,008,139 has been obligated on UM1AI164556: $27,799,806 in federal funding and $208,333 in non-federal funding.
Which agency awarded UM1AI164556?
National Institute of Allergy and Infectious Diseases (National Institutes of Health) awarded UM1AI164556, with funding from National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award